{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T05:24:46Z","timestamp":1793683486379,"version":"4.5.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T00:00:00Z","timestamp":1271289600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1007\/s10067-010-1445-z","type":"journal-article","created":{"date-parts":[[2010,4,14]],"date-time":"2010-04-14T05:57:34Z","timestamp":1271224654000},"page":"467-475","source":"Crossref","is-referenced-by-count":16,"title":["Awareness of Fabry disease among rheumatologists\u2014current status and perspectives"],"prefix":"10.1007","volume":"30","author":[{"given":"Rolando","family":"Cimaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Hilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Manger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Torvin M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico M.","family":"Wulffraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,15]]},"reference":[{"key":"1445_CR1","first-page":"3733","volume-title":"The metabolic and molecular bases of inherited disease","author":"RJ Desnick","year":"2001","unstructured":"Desnick RJ, Ioannou YA, Eng CM (2001) a-Galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733\u20133774"},{"key":"1445_CR2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry registry. Pediatr Res 64:550\u2013555","journal-title":"Pediatr Res"},{"key":"1445_CR3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","volume":"95","author":"U Ramaswami","year":"2006","unstructured":"Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey. Acta Paediatr 95:86\u201392","journal-title":"Acta Paediatr"},{"key":"1445_CR4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767\u2013776","journal-title":"Am J Kidney Dis"},{"key":"1445_CR5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A et al (2007) Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228\u20131235","journal-title":"Eur Heart J"},{"key":"1445_CR6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","volume":"23","author":"A Ortiz","year":"2008","unstructured":"Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 23:1600\u20131607","journal-title":"Nephrol Dial Transplant"},{"key":"1445_CR7","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102\u20132111","journal-title":"Nephrol Dial Transplant"},{"key":"1445_CR8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","volume":"40","author":"K Sims","year":"2009","unstructured":"Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events. Natural history data from the Fabry Registry. Stroke 40:788\u2013794","journal-title":"Stroke"},{"key":"1445_CR9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/jmg.2005.036327","volume":"43","author":"PB Deegan","year":"2006","unstructured":"Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43:347\u2013352","journal-title":"J Med Genet"},{"key":"1445_CR10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"1445_CR11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","volume":"9","author":"RY Wang","year":"2007","unstructured":"Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9:34\u201345","journal-title":"Genet Med"},{"key":"1445_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000060196","volume":"136","author":"C Whybra","year":"2001","unstructured":"Whybra C, Wendrich K, Ries M, Gal A, Beck M (2001) Clinical manifestation in female Fabry disease patients. Contrib Nephrol 136:245\u2013250","journal-title":"Contrib Nephrol"},{"key":"1445_CR13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112\u2013128","journal-title":"Mol Genet Metab"},{"key":"1445_CR14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","volume":"17","author":"DA Laney","year":"2008","unstructured":"Laney DA, Fernhoff PM (2008) Diagnosis of Fabry disease via analysis of family history. J Genetic Couns 17:79\u201383","journal-title":"J Genetic Couns"},{"key":"1445_CR15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","volume":"30","author":"WL Hwu","year":"2009","unstructured":"Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat 30:1397\u20131405","journal-title":"Hum Mutat"},{"key":"1445_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79:31\u201340","journal-title":"Am J Hum Genet"},{"key":"1445_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"1445_CR18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ et al (2007) Sustained, long-term renal stabilization after 54\u00a0months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"1445_CR19","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","volume":"18","author":"R Schiffmann","year":"2007","unstructured":"Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18:1576\u20131583","journal-title":"J Am Soc Nephrol"},{"key":"1445_CR20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","volume":"119","author":"F Weidemann","year":"2009","unstructured":"Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S et al (2009) Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524\u2013529","journal-title":"Circulation"},{"key":"1445_CR21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1651-2227.2002.tb03108.x","volume":"91","author":"MJ Hilz","year":"2002","unstructured":"Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91:38\u201342","journal-title":"Acta Paediatr Suppl"},{"key":"1445_CR22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750\u2013760","journal-title":"J Med Genet"},{"key":"1445_CR23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ncpneuro0407","volume":"3","author":"AT Moller","year":"2007","unstructured":"Moller AT, Jensen TS (2007) Neurological manifestations in Fabry's disease. Nat Clin Pract Neurol 3:95\u2013106","journal-title":"Nat Clin Pract Neurol"},{"key":"1445_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2009.06.032","volume":"145","author":"A Torvin Moller","year":"2009","unstructured":"Torvin Moller A, Winther Bach F, Feldt-Rasmussen U, Rasmussen A, Hasholt L, Lan H et al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145:237\u2013245","journal-title":"Pain"},{"key":"1445_CR25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2002.tb03110.x","volume":"91","author":"R Schiffmann","year":"2002","unstructured":"Schiffmann R, Scott LJ (2002) Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 91:48\u201352","journal-title":"Acta Paediatr Suppl"},{"key":"1445_CR26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ (2008) Fabry's disease. Lancet 372:1427\u20131435","journal-title":"Lancet"},{"key":"1445_CR27","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","volume":"30","author":"AL Cole","year":"2007","unstructured":"Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH (2007) Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis 30:943\u2013951","journal-title":"J Inherit Metab Dis"},{"key":"1445_CR28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1651-2227.2002.tb03107.x","volume":"91","author":"F Birklein","year":"2002","unstructured":"Birklein F (2002) Mechanisms of neuropathic pain and their importance in Fabry disease. Acta Paediatr Suppl 91:34\u201337","journal-title":"Acta Paediatr Suppl"},{"key":"1445_CR29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00004691-200212000-00011","volume":"19","author":"M Dutsch","year":"2002","unstructured":"Dutsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19:575\u2013586","journal-title":"J Clin Neurophysiol"},{"key":"1445_CR30","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.clinph.2008.02.004","volume":"119","author":"SM Laaksonen","year":"2008","unstructured":"Laaksonen SM, Roytta M, Jaaskelainen SK, Kantola I, Penttinen M, Falck B (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119:1365\u20131372","journal-title":"Clin Neurophysiol"},{"key":"1445_CR31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","volume":"26","author":"CA Luciano","year":"2002","unstructured":"Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM et al (2002) Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve 26:622\u2013629","journal-title":"Muscle Nerve"},{"key":"1445_CR32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","volume":"31","author":"S Al Sawaf","year":"2008","unstructured":"Al Sawaf S, Mayatepek E, Hoffmann B (2008) Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed. J Inherit Metab Dis 31:473\u2013480","journal-title":"J Inherit Metab Dis"},{"key":"1445_CR33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1517\/14656566.6.3.489","volume":"6","author":"JE Wraith","year":"2005","unstructured":"Wraith JE (2005) The first 5\u00a0years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6:489\u2013506","journal-title":"Expert Opin Pharmacother"},{"key":"1445_CR34","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/BF02283120","volume":"11","author":"SO Paira","year":"1992","unstructured":"Paira SO, Roverano S, Iribas JL, Barcelo HA (1992) Joint manifestations of Fabry's disease. Clin Rheumatol 11:562\u2013565","journal-title":"Clin Rheumatol"},{"key":"1445_CR35","first-page":"177","volume":"31","author":"D Wise","year":"1962","unstructured":"Wise D, Wallace HJ, Jellinek EH (1962) Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med 31:177\u2013206","journal-title":"Q J Med"},{"key":"1445_CR36","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/art.10391","volume":"46","author":"H Horiuchi","year":"2002","unstructured":"Horiuchi H, Saito N, Kobayashi S, Ota H, Taketomi T, Takaoka K (2002) Avascular necrosis of the femoral head in a patient with Fabry's disease: identification of ceramide trihexoside in the bone by delayed-extraction matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum 46:1922\u20131925","journal-title":"Arthritis Rheum"},{"key":"1445_CR37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4263\/jorthoptic.34.192","volume":"34","author":"YH Lien","year":"2005","unstructured":"Lien YH, Lai LW (2005) Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease. Am J Orthop 34:192\u2013194","journal-title":"Am J Orthop"},{"key":"1445_CR38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1001\/archderm.1955.03730360062007","volume":"72","author":"RB Pittelkow","year":"1955","unstructured":"Pittelkow RB, Kierland RR, Montgomery H (1955) Angiokeratoma corporis diffusum. AMA Arch Derm 72:556\u2013561","journal-title":"AMA Arch Derm"},{"key":"1445_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3928\/0147-7447-19930401-12","volume":"16","author":"G Ross","year":"1993","unstructured":"Ross G, Kuwamura F, Goral A (1993) Association of Fabry's disease with femoral head avascular necrosis. Orthopedics 16:471\u2013473","journal-title":"Orthopedics"},{"key":"1445_CR40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/BF00296520","volume":"90","author":"M Uchino","year":"1995","unstructured":"Uchino M, Uyama E, Kawano H, Hokamaki J, Kugiyama K, Murakami Y et al (1995) A histochemical and electron microscopic study of skeletal and cardiac muscle from a Fabry disease patient and carrier. Acta Neuropathol 90:334\u2013338","journal-title":"Acta Neuropathol"},{"key":"1445_CR41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","volume":"68","author":"DP Germain","year":"2005","unstructured":"Germain DP, Benistan K, Boutouyrie P, Mutschler C (2005) Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet 68:93\u201395","journal-title":"Clin Genet"},{"key":"1445_CR42","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","volume":"9","author":"H Mersebach","year":"2007","unstructured":"Mersebach H, Johansson JO, Rasmussen AK, Bengtsson BA, Rosenberg K, Hasholt L et al (2007) Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet Med 9:812\u2013818","journal-title":"Genet Med"},{"key":"1445_CR43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cccn.2004.10.019","volume":"353","author":"GE Linthorst","year":"2005","unstructured":"Linthorst GE, Vedder AC, Aerts JM, Hollak CE (2005) Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta 353:201\u2013203","journal-title":"Clin Chim Acta"},{"key":"1445_CR44","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 34:236\u2013242","journal-title":"Eur J Clin Invest"},{"key":"1445_CR45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1651-2227.2007.00198.x","volume":"96","author":"SC Garman","year":"2007","unstructured":"Garman SC (2007) Structure-function relationships in alpha-galactosidase A. Acta Paediatr Suppl 96:6\u201316","journal-title":"Acta Paediatr Suppl"},{"key":"1445_CR46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M, Gaggioli D (2001) Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 308:195\u2013196","journal-title":"Clin Chim Acta"},{"key":"1445_CR47","doi-asserted-by":"crossref","unstructured":"Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE (2009) Screening for Fabry disease in high risk populations: a systematic review. J Med Genet (in press)","DOI":"10.1136\/jmg.2009.072116"},{"key":"1445_CR48","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s10545-007-0679-7","volume":"30","author":"Z Lukacs","year":"2007","unstructured":"Lukacs Z, Hartung R, Beck M, Keil A, Mengel E (2007) Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients. J Inherit Metab Dis 30:614","journal-title":"J Inherit Metab Dis"},{"key":"1445_CR49","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","volume":"69","author":"RM Schaefer","year":"2009","unstructured":"Schaefer RM, Tylki-Szymanska A, Hilz MJ (2009) Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs 69:2179\u20132205","journal-title":"Drugs"},{"issue":"Suppl A","key":"1445_CR50","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0149-2918(07)80115-9","volume":"29","author":"C Wanner","year":"2007","unstructured":"Wanner C (2007) Fabry disease model: a rational approach to the management of Fabry disease. Clin Ther 29(Suppl A):S2\u2013S5","journal-title":"Clin Ther"},{"key":"1445_CR51","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933\u20131946","journal-title":"Kidney Int"},{"key":"1445_CR52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease. N Engl J Med 345:9\u201316","journal-title":"N Engl J Med"},{"key":"1445_CR53","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/01.WNL.0000118207.84514.40","volume":"62","author":"MJ Hilz","year":"2004","unstructured":"Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M (2004) Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 62:1066\u20131072","journal-title":"Neurology"},{"key":"1445_CR54","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"1445_CR55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65\u201374","journal-title":"Am J Hum Genet"},{"key":"1445_CR56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345\u2013354","journal-title":"Nephrol Dial Transplant"},{"key":"1445_CR57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10545-009-1290-x","volume":"32","author":"A Keilmann","year":"2009","unstructured":"Keilmann A, Hajioff D, Ramaswami U (2009) Ear symptoms in children with Fabry disease: data from the Fabry Outcome Survey. J Inherit Metab Dis 32:739\u2013744","journal-title":"J Inherit Metab Dis"},{"key":"1445_CR58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8:539\u2013548","journal-title":"Genet Med"},{"key":"1445_CR59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.survophthal.2008.04.005","volume":"53","author":"N Samiy","year":"2008","unstructured":"Samiy N (2008) Ocular features of Fabry disease: diagnosis of a treatable life-threatening disorder. Surv Ophthalmol 53:416\u2013423","journal-title":"Surv Ophthalmol"},{"key":"1445_CR60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2215\/CJN.08091109","volume":"5","author":"U Ramaswami","year":"2010","unstructured":"Ramaswami U, Najafian B, Schieppati A, Mauer M, Bichet DG (2010) Assessment of renal pathology and dysfunction in children with Fabry disease. Clin J Am Soc Nephrol 5:365\u2013370","journal-title":"Clin J Am Soc Nephrol"},{"key":"1445_CR61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CRD.0b013e31818adc50","volume":"17","author":"B Pierre-Louis","year":"2009","unstructured":"Pierre-Louis B, Kumar A, Frishman WH (2009) Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev 17:31\u201335","journal-title":"Cardiol Rev"},{"key":"1445_CR62","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E et al (2008) Onset and progression of the Anderson\u2013Fabry disease related cardiomyopathy. Int J Cardiol 130:367\u2013373","journal-title":"Int J Cardiol"},{"key":"1445_CR63","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1001\/archneur.60.11.1524","volume":"60","author":"RH Dworkin","year":"2003","unstructured":"Dworkin RH, Backonja M, Rowbotham MC et al (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524\u20131534","journal-title":"Arch Neurol"},{"key":"1445_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e3282f57da5","volume":"2","author":"R Baron","year":"2008","unstructured":"Baron R, Tolle TR (2008) Assessment and diagnosis of neuropathic pain. Curr Opin Support Palliat Care 2:1\u20138","journal-title":"Curr Opin Support Palliat Care"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1445-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1445-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T01:02:47Z","timestamp":1635210167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1445-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,15]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1445-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,15]]}}}